• NeOnc Technologies secured an FDA meeting in early January 2027 to discuss potential accelerated approval for intranasal NEO100.
• The proposed Phase 3 trial would compare NEO100 with chemotherapy in recurrent or progressive IDH-mutant grade 4 astrocytoma.
• Phase 2a results, already reported on August 12, 2026, showed progression-free survival exceeded the trial’s standard-of-care benchmark.
• No serious treatment-related adverse events were reported; treatment-related side effects were mild to moderate, predominantly affecting the nose or upper airway.
• Enrollment in the confirmatory trial is expected to be ongoing at any application submission; survival results would support conversion to traditional approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611110800PRIMZONEFULLFEED9875261) on November 11, 2026, and is solely responsible for the information contained therein.